Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Lupin Pharmaceuticals, Inc
Lobbying Relationship
Bills mentioned
H.R.2051: FAST Generics Act of 2017
Sponsor: David McKinley (R-W.Va.)
H.R.2212: CREATES Act of 2017
Sponsor: Tom Marino (R-Pa.)
H.R.749: Lower Drug Costs through Competition Act
Sponsor: Kurt Schrader (D-Ore.)
H.R.2430: FDA Reauthorization Act of 2017
Sponsor: Greg Walden (R-Ore.)
H.R.1892: Bipartisan Budget Act of 2018
Sponsor: John B. Larson (D-Conn.)
H.R.1625: Consolidated Appropriations Act, 2018
Sponsor: Edward Royce (R-Calif.)
S.974: Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Sponsor: Patrick J. Leahy (D-Vt.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Henry Menn III | COS, Sen. Bob Graham (01-04) Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commiss (93-95) CoS, Sen. Bob Graham (2001 - 2004); Min SD & Counsel, Cmte on Vet Affairs (2004); Sp Asst Leg Aff, FDA Office of Commissioner (1993-1995) |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate